A new strategy based on pharmacophore-based virtual screening in adenosine deaminase inhibitors detection and in-vitro study

DARU, Journal of Pharmaceutical Sciences

Volumn 20, Issue 1, 2012, Pages

  Bazl, Roya ^a,b   Ganjali, Mohammad Reza ^a   Saboury, Ali Akbar ^a   Foroumadi, Alireza ^b   Nourozi, Parviz ^a   Amanlou, Massoud ^b  

^a UNIVERSITY OF TEHRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adenosine deaminase; Docking; Inhibitor; Lead discovery; Pharmachophore

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE INHIBITOR; NATURAL PRODUCT;

ARTICLE; DRUG POTENCY; DRUG SCREENING; ENZYME INHIBITION; ENZYME STRUCTURE; FLUORESCENCE SPECTROSCOPY; IC 50; IN VITRO STUDY; MICHAELIS CONSTANT; MOLECULAR DOCKING; MOLECULAR MODEL; PHARMACOPHORE; PREDICTION; ULTRAVIOLET SPECTROSCOPY; VALIDATION STUDY; VIRTUAL REALITY;

EID: 84870652863     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-20-64     Document Type: Article

References (27)

1. Functional residues at the active site of bovine brain adenosine deaminase. Lupidi G, Marmocchi F, Venardi G, Cristalli G, Biochem Mol Biol Int 1997 43 1339 1352 9442929 (Pubitemid 28022328)
2. Purification of adenosine deaminase from the superficial mucosa of calf intestine. Brady TG, O'Connell WA, Biochim Biophys Acta 1962 62 216 229 10.1016/0006-3002(62)90035-5 13872365
3. Adenosine deaminase prefer s a distinct sugar ring conformation for binding and catalysis: kinetic and structural studies. Ford H, Dai F, Mu L, Siddiqui MA, Nicklaus MC, Anderson L, Marquez VE, Barchi JJ, Biochemistry 2000 39 2581 2592 10.1021/bi992112c 10704207 (Pubitemid 30148910)
4. Complexes of adenosine deaminase with two potent inhibitors. Wang Z, Quiocho FA, Biochemistry 1998 37 8314 8324 10.1021/bi980324o 9622483 (Pubitemid 28275450)
5. The role of adenosine and 2' -deoxyadenosine in mammalian cells. Fox IH, Kelley WN, Annu Rev Biochem 1978 47 655 686 10.1146/annurev.bi.47.070178.003255 209731
6. Adenosine deaminase: functional implications and different classes of inhibitors. Cristalli G, Costanzi S, Lambertucci C, Lupidi G, Vittori S, Volpini R, Camaioni E, Med Res Rev 2001 21 105 128 10.1002/1098-1128(200103)21: 2<105::AID-MED1002>3.0.CO;2-U 11223861 (Pubitemid 32185243)
7. Elevated adenosine deaminase and purine nucleoside phosphorylase activity in peripheral blood null lymphocytes from patients with acquired immune deficiency syndrome. Murray JL, Loftin KC, Munn CG, Reuben JM, Mansell PWA, Hersh EM, Blood 1985 65 1318 1324 3922455 (Pubitemid 15057937)
8. Changes of serum adenosine deaminase activity induced by stress in rats. Miyahara S, Komori T, Shizuya K, Nomura J, Human Psychopharm 1998 13 325 327 10.1002/(SICI)1099-1077(199807)13:5<325::AID-HUP3>3.0.CO;2-7 (Pubitemid 28358160)
9. Regulation of adenosine formation by the heart. Sparks HV, Bardenheuer H, Circ Res 1986 58 193 201 10.1161/01.RES.58.2.193 3004778 (Pubitemid 16107743)
10. Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938. Kuno M, Seki N, Tsujimoto S, Nakanishi I, Kinoshita T, Nakamura K, Terasaka T, Nishio N, Sato A, Fujii T, Eur J Pharmacol 2006 534 241 249 10.1016/j.ejphar.2006.01.042 16515782 (Pubitemid 43384207)
11. Pentostatin: Future directions. Klohs WD, Kraker AJ, Pharmacol Rev 1992 44 459 477 1480666 (Pubitemid 23014353)
12. Adenosine for vasoreactivity testing in pulmonary hypertension: A head-to-head comparison with inhaled nitric oxide. Edmundo C, Antonio Luiz P, Carlos Faria Santos A, Resp Med 2010 104 Edmundo C, Antonio Luiz P, Carlos Faria Santos A 606 611
13. Dioxolane guanosine, the active for m of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. Mewshaw JP, Myrick FT, Wakefield DA, Hooper BJ, Harris JL, McCreedy B, Borroto-Esoda K, J Acquir Immune Defic Syndr 2002 29 11 20 11782585 (Pubitemid 34094302)
14. Adenosine deaminase inhibitors: Their role in chemotherapy and immunosuppression. Glaze RI, Cancer Chemo Pharmacol 1980 4 227 235
15. Inhibition of ribonuclease A by polyphenols present in green tea. Ghosh KS, Maiti TK, Debnath J, Dasgupta S, Proteins 2007 69 566 580 10.1002/prot.21484 17623866 (Pubitemid 47623872)
16. Tea and health. Balentine D, Crit Rev Food Sci Nutr 1997 37 691 692 10.1080/10408399709527796
17. Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo. Mitchell BS, Koller CA, Heyn R, Blood 1980 56 556 559 6967747 (Pubitemid 11251042)
18. Inhibition of carcinogenesis by tea: The evidence from experimental studies. Dreosti IE, Wargovich MJ, Yang CS, Crit Rev Food Sci Nutr 1997 37 761 70 10.1080/10408399709527801 9447274 (Pubitemid 127348900)
19. Evaluation of the antioxidant potential of natural products. Lee SK, Mbwambo ZH, Chung H, Luyengi L, Gamez EJ, Mehta RG, Kinghorn AD, Pezzuto JM, Comb Chem High Throughput Screen 1998 1 35 46 10499128 (Pubitemid 128541767)
20. Recent developments in anti-inflammatory natural products. Gautam R, Jachak SM, Med Res Rev 2009 29 767 820 10.1002/med.20156 19378317
21. Anti-carcinogenic activity of d-limonene during the initiation and promotion/progression stages of DMBA-induced rat mammary carcinogenesis. Elson CE, Maltzman TH, Boston JL, Tanner MA, Gould MN, Carcinogenesis 1988 9 331 332 10.1093/carcin/9.2.331 3123086 (Pubitemid 18038001)
22. Virtual screening for lead discovery. Tang YT, Marshall GR, Methods Mol Biol 2011 716 1 22 10.1007/978-1-61779-012-6-1 21318897
23. Large-scale virtual screening for the identification of new Helicobacter pylori urease inhibitor scaffolds. Azizian H, Nabati F, Sharifi A, Siavoshi F, Mahdavi M, Amanlou M, J Mol Model 2011 18 2917 2927 22139480
24. Kinetic and structural analysis of the inhibition of adenosine deaminase by acetaminophen. Ataie G, Safarian S, Divsalar A, Saboury AA, Moosavi-Movahedi AA, Ranjbar B, Cristalli G, Mardanian S, J Enz Inhib Med Chem 2004 19 71 78 10.1080/14756360310001632741 (Pubitemid 38239932)
25. Kinetics of inhibition of calf intestinal adenosine deaminase by (+)- and ()-erythro-9-(2-hydr oxy-3-nonyl)adenine. Porter DJ, Abushanab E, Biochemistry 1992 35 8216 8220
26. The inhibitory effect of ethylenediamine on mushroom tyrosinase. Alijanianzadeh M, Saboury AA, Ganjali MR, Hadi-Alijanvand H, Moosavi-Movahedi AA, Int J Biol Macromol 2012 50 573 577 10.1016/j.ijbiomac.2012.01.030 22313842
27. Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: Predicting enzyme conformational change and metabolism. Terasaka T, Tsuji K, Kato T, Nakanishi I, Kinoshita T, Kato Y, Kuno M, Inoue T, Tanaka K, Nakamura K, J Med Chem 2005 48 4750 4753 10.1021/jm050413g 16033254 (Pubitemid 41033118)